Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 30 Sept 2014 |
| Zealand to present at three healthcare conferences in September 2014 | 27 Aug 2014 |
| Zealand Pharma A/S ─ Interim report for H1 2014 (un-audited) | 21 Aug 2014 |
| Zealand reports increased Lyxumia® royalty revenue for H1 2014 and informs of status update as provided by Sanofi | 31 Jul 2014 |
| Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines | 28 Jul 2014 |